|
|
|
Debbie Allison, M.S.
Senior Director, Global Corporate Licensing
Merck
Debbie Allison is Senior Director of Global Competitive Intelligence at Merck & Co., Inc. She has been with Merck for 30 years and worked in the competitive
intelligence arena for over 9 years. Debbie leads the effort to ensure that Merck's competitive and strategic information systems and processes remain premier
within the industry. Her responsibilities also include providing competitive intelligence to the oncology franchise.
Debbie earned a Bachelor's degree in chemistry from The College of William and Mary and a Master's degree in medicinal chemistry from The Ohio State
University. Debbie joined Merck in 1979 as a Medicinal Chemist, supporting programs focused on discovery and development of anti-inflammatory agents.
Debbie left the labs in the mid 1980s to lead a cross-divisional, international effort to put real-time chemical structure and reaction information at the chemist's
desktop through a complete transformation of computer-based information systems. The subsequent move to the Competitive Information group was a perfect
fit for Debbie's talent in assimilating data and computer systems with user's need for strategic insight.
"My passion is to utilize scientific and business information to help establish strategic direction for Merck."
_____________________________________________________________________________________________________________________________
|
|
|
|
Roland Andersson
Senior Managing Director, Strategic Advisors
Leerink Swann & Co
ROLAND ANDERSSON, Ph.D., has extensive experience working with biotechnology, pharmaceutical, medical device and diagnostic companies, with
primary expertise in strategy, transaction support, post-merger integration and R&D strategy. Dr. Andersson has previously served as the Senior Managing
Director of Leerink Swann Strategic Advisors, and built this group to become a major part of the firm. Prior to joining Leerink Swann Strategic Advisors, Dr.
Andersson held positions as a Senior Partner at Strategic Decisions Group and the Global Practice Leader for Arthur D. Little Inc. Dr. Andersson started his
career at Pharmacia Corporation, where he held a number of management positions in Development, Marketing and Quality Assurance. Dr. Andersson
received an MS in Engineering and a Ph.D. (Teknisk Licentiat) degree in Management from Linkoping Institute of Technology (Sweden). His research work was
in the area of integrated product development processes within industrial companies, and his thesis work, published as a book, is currently in the third printing.
___________________________________________________________________________________________________________
|
| |
|
Jennifer Breen Andreasson
Worldwide Regulatory Policy and Intelligence
Pfizer
Jennifer Breen Andreasson has over 10 years experience in the pharmaceutical industry with a focus and expertise in US, EU, and Rest of World regulatory
strategy. After an internship at Pfizer’s office in Spain , she began her career at Pfizer in the Worldwide Labeling Group, where she supported the
CV/Metabolic/Pain/Inflammation therapy areas. Jennifer then took an assignment with Europe/Canada Regulatory Strategy Group working on
CNS/Pain/Inflammation products in Brussels , Belgium and Walton Oaks, UK . Upon completion of her expatriate assignment, Jennifer returned to the
Worldwide Regulatory Strategy group in NY and supported products in the CNS therapy area. Prior to her current role as Associate Director, Competitive
Intelligence, Jennifer was the Global Regulatory Lead for Viagra.
Jennifer holds a Bachelor’s degree from the University of Scranton and a certificate from the Universidad de Barcelona. She speaks Spanish, Italian, and
Portuguese.
She is a member of DIA and the DIA Regulatory Affairs SIAC Intelligence Working Group.
_____________________________________________________________________________________________________________________________
|
| |
|
Jeff Beeny
Manager of Corporate Strategy
Thermo Fisher Scientific
Jeffrey Beeny is the Senior Manager of Business Intelligence at Thermo Fisher Scientific.
From May 2006 through November 2006, he was a key member of the Fisher Scientific anti-trust team working on the company’s $10.6 billion merger with
Thermo Electron. In support of the company’s regulatory filings, Mr. Beeny managed the business intelligence process, an essential component of approval
from the Federal Trade Commission (FTC) and European Commission (EC). He joined Fisher Scientific in January 2006 with the responsibility for strategic,
market and competitive analysis in support of corporate initiatives and strategic decision-making.
Prior to joining Fisher Scientific, Mr. Beeny was the Principal Market Analyst, Competitive Intelligence at EMC Corporation. At EMC, Mr. Beeny was
responsible for competitive and market analysis for the company’s corporate strategy focused on information lifecycle management. Prior to EMC, he was the
Manager of Competitive Intelligence at Genuity, where he led competitive and strategic analysis initiatives for senior management. In the mid- to late-1990s,
Mr. Beeny was a Risk Financing Analyst at Liberty Mutual and a Scientist for The Gillette Company - Duracell. He holds a B.S. General Science in Chemistry
from Purdue University and earned an M.B.A. in Finance and Strategy from Boston College. Mr. Beeny has been a member of the Society of Competitive
Intelligence Professionals since 2000.
_____________________________________________________________________________________________________________________________
|
| |
|
Rachid Benhamza
Director Product Management
Commercial Operations
Helsinn Healthcare S.A.
_____________________________________________________________________________________________________________________________
|
| |
|
Eduardo Flores Bermudez (invited)
Specialist for Competitive Intellignece
Bayer Schering Pharma AG
Chair of the Board of Directors
Society of Competitive Intelligence Professionals (SCIP)
_____________________________________________________________________________________________________________________________
|
|
|
|
Stan Bernard
President
Bernard Associates, LLC
Stan Bernard, MD, MBA is the Founder and President of Bernard Associates (www.BernardAssociatesLLC.com), a pharmaceutical and health care industry
management consulting firm that offers strategic planning, marketing, competitive simulations (war games), competitive planning, and business development
services. The firm thrives on the cutting-edge: new products, technologies, services, ventures, markets, customer segments, opportunities, challenges, and
issues. Bernard Associates has worked with nine of the top ten pharmaceutical companies and many of the leading biopharmaceutical, medical device,
diagnostics, and health care products companies.
Dr. Bernard is nationally recognized as a health care and pharmaceutical industry consultant, speaker, and author. He has been featured on national
television and in leading publications, including the Wall Street Journal, Business 2.0, and Business Week. He has published over 50 book chapters and
articles on health care and pharmaceutical topics.
Previously, Dr. Bernard served as a Principal in the Health Care and Pharmaceutical Industry Consulting Practice at A.T. Kearney. Prior to joining A.T.
Kearney, Dr. Bernard worked at Bristol-Myers Squibb Pharmaceutical Company where he held several executive business and medical positions. He served as
U.S. Product Manager for the launch of the cholesterol-lowering drug Pravachol, Bristol-Myers Squibb’s most successful pharmaceutical product. He served as
U.S. Managed Care Medical Director, the first person to hold such a position in the pharmaceutical industry, and as U.S. Director - Pharmacoeconomics.
Previous positions included those in Worldwide Business Development, U.S. Medical Operations, and U.S. Medical Services.
Dr. Bernard is a former Senior Fellow in the Health Care Systems Department at The Wharton School of Business where he initiated and taught in the
“Pharmaceutical Management” course for fourteen years. Dr. Bernard is the recipient of the prestigious Wharton School of Business Alumni Achievement
Award for his contributions to Wharton and the health care industry. Dr. Bernard received his M.B.A. in marketing and health care management from the
Wharton School of Business. He received his Medical Degree from Baylor College of Medicine.
_____________________________________________________________________________________________________________________________
|
|
|
|
Chris Bogan
CEO
Best Practices
Chris Bogan is the Chief Executive Officer and Founder of Best Practices®, LLC, a leader in the field of best practice performance improvement. Based in
Chapel Hill, North Carolina, Best Practices®, LLC specializes in providing pharmaceutical, biotechnology and medical device corporations throughout the
world with business intelligence, research, benchmarking studies, and consulting services. The company's products and services provide corporations with
"Access And Intelligence For Achieving World-Class Excellence™."
Mr. Bogan received his MBA with honors from the Harvard Business School and his bachelor's degree magna cum laude from Amherst College. He was a
Nieman Fellow at Harvard University. Mr. Bogan's work has focused on organizational excellence, blockbuster product launches, marketing excellence, sales
force effectiveness, clinical operations and best practice improvement strategies. He has written about numerous aspects of performance excellence and
continuous improvement. In recent years, he has concentrated on ways that companies can use best practice insights to create economic value, accelerate
revenue and profit growth, and drive rapid performance improvement. He is co-author of the widely acclaimed books, Benchmarking For Best Practices:
Winning Through Innovative Adaptation, published by McGraw-Hill, and The Baldrige: What It Is, How It's Won, and How To Use It To Improve Quality In Your
Company.
Mr. Bogan has consulted on performance improvement and best practice competitiveness issues for a wide range of pharmaceutical, biotechnology and
medical device companies, including Pfizer, Eli Lilly, GlaxoSmithKline, Genentech, J&J, Amylin, Sanofi-Aventis, AstraZeneca, Amgen, Novartis, Roche,
Baxter Healthcare, Bayer, 3M Pharmaceuticals, Abbott Laboratories, Astellas, LifeScan, Guidant, Janssen Pharmaceutica and others.
Mr. Bogan led the consulting teams that assisted both Federal Express and GTE Directories (now Verizon) in winning the prestigious Malcolm Baldrige
National Quality Award. He has also advised many leading corporations outside the healthcare sector, including industry leaders such as Microsoft, American
Express, AT&T, General Motors, BellSouth, Chevron, Exxon, Xerox, Verizon, Marriott, Merrill Lynch, Siemens, KPMG, the New York Times Company, J.P.
Morgan Chase & Co., TIAACREF, Nortel Networks, Pitney Bowes, Bank of America, Wachovia and many others.
A guest lecturer at Northwestern University’s Kellogg School of Management and the University of North Carolina’s (UNC) Kenan Flagler Business School, Mr.
Bogan has spoken widely before business audiences in North America, Europe, Asia and Latin America. He is an advisor to various management magazines on
best practice and management issues. He currently serves on the UNC Academic Leadership Institute’s National Advisory Board. Previously, he served on the
Board of Directors of Ontogeny, Inc., a stem cell and functional genomics company now named Curis, Inc.
Prior to founding Best Practices, LLC, Mr. Bogan was a principal and founding member of The TQM Group, Ltd., a Bostonbased consultancy. Mr. Bogan also
spent many years working at various media companies, including Times Mirror Corp., Knight-Ridder Inc., Howard Publications and Cowles Publishing Co. He
has contributed articles to many newspapers and magazines, including The Harvard Business Review, Time, Pharmaceutical Executive, PharmaVoice,
MedAd News, Planning Review, The Los Angeles Times, The Boston Globe, The Miami Herald, The Chicago Tribune and The Philadelphia Inquirer.
Through his work, Mr. Bogan has toured manufacturing and service companies throughout the world.
_____________________________________________________________________________________________________________________________
|
| |
|
Paul Bould
Head of Competitive Intelligence
Bayer Healthcare
_____________________________________________________________________________________________________________________________
|
| |
|
Linda Bowen
Director Regulatory Intelligence and Policy
sanofi aventis
Linda is Director of Regulatory Intelligence and Policy at sanofi-aventis and has held senior regulatory affairs positions at Bayer Healthcare and Block
Drug/GlaxoSmithKline, with global regulatory responsibilities for submissions, life cycle management and due diligence activities. She holds degrees in
Microbiology and English from Rutgers University and an M.S. in Drug Regulatory Affairs from LIU, where she was inducted into the Rho Chi Society. She is a
member of the RAPs Board of Directors, DIA, TOPRA, an editor for the 2004 RAPS publication "Fundamentals in Canadian Regulatory Affairs", Chair of the
NJ/NY RAPs Chapter, past co-chair of the global briefings track (2002 & 2005 Annual RAPs Meetings) and the 1st Canadian RAPs Conference (2004), as well
as a frequent speaker and author on various regulatory affairs topics. She has attained regulatory affairs certification (RAC) for the US, Canada and Europe.
She is the coordinator for the DIA Regulatory Affairs SIAC and past chair of the DIA Regulatory Affairs SIAC Intelligence Working Group.
_____________________________________________________________________________________________________________________________
|
|
|
|
Branimir Brankov, M.D., M.B.A.
Sr. Director Strategic Business Intelligence
Merck & Co., Inc.
Dr. Branimir Brankov is a professional manager and marketer with a medical and business background and more than 15 years experience in the
pharmaceutical industry.
Dr. Brankov is currently responsible for Strategic Business Intelligence Group which is part of the Global Competitive Intelligence Unit established in the Merck
Headquarter in Whitehouse Station, N.J., U.S.A. In this capacity, his main functions include managing global projects and initiatives, conducting competitive
analysis and providing guidance to Merck Executives and Global Marketing Teams on strategy development.
In his previous roles at Merck, Dr. Brankov has been Global Leader for Physician Communities of Practice initiative at Merck. As part of the Global market
research team in Merck Headquarter he has been responsible for providing global market research and business intelligence support for several therapeutic
areas. Before his assignments in Merck Headquarter Dr. Brankov was responsible for establishing and managing independent subsidiaries for Merck & Co., Inc.
in Bulgaria, Macedonia and Albania.
Dr. Brankov received his M.D. from the Medical University of Sofia and practiced at the Military Medical Academy in Sofia, Bulgaria, specializing in
Neurosurgery. In 2001, he obtained a Masters’ Degree in Economics from the Economics University of Sofia, with concentration in Human Resources; and, in
2003, he earned a Masters’ Degree in Business Administration from Rutgers University, New Jersey, with concentration in Marketing and Management. He is
active member of PBIRG, SCIP and MRII.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Carole Bruckler
Business Unit Director
Deallus Group
_____________________________________________________________________________________________________________________________
|
| |
|
Jim Caldwell
Senior Consultant
Fletcher/CSI
Mr. Caldwell has more than 15 years experience in executive level financial analysis including mergers and acquisitions, business development, and P&L
analysis. He has conducted numerous studies across all of Fletcher/CSI’s practice areas including working with many pharmaceutical and medical device
companies in identifying M & A targets. Prior to joining Fletcher/CSI, Mr. Caldwell held several senior level positions with such organizations as Morgan
Stanley, Prudential Insurance, and Cabletron Systems. Over the years, Mr. Caldwell’s experience has included heading up Investor Relations, global sales
training, supply chain management, M & A identification, company divestitures, and inter-continental partner communication and coordination. Mr. Caldwell
will share with you some of the knowledge he has accumulated over the years and how this information can be used to help your company identify qualified
targeted M & A opportunities.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kurt Cannon
Director
Genzyme
Kurt is Director of Competitive and Technical Intelligence (CTI) at Genzyme Corp. He manages the team that provides strategic market intelligence to
Genzyme’s Transplant, Oncology and Multiple Sclerosis business. In addition, Kurt heads CTI’s Science Intelligence Group and is actively involved in efforts
to maximize the odds of success for Genzyme Science initiatives. Prior to Genzyme Kurt was a Pharmaceutical Market Consultant at Decision Resources
Consulting, where he conducted strategic assessments such as market opportunity and optimal points of market entry for emerging therapeutics and medical
devices.
Kurt has scientific expertise in oncology, immunology and cell biology. He has a PhD in Cell Biology from Yale University, conducted research at Kyoto
University in Japan, and was a post-doctoral Fellow of the Leukemia and Lymphoma Society at the Harvard Medical School.
_____________________________________________________________________________________________________________________________
|
| |
|
Claudio D’Ambrosio, PhD, MSc
Business Unit Director
Deallus Group
Claudio is Director of the Oncology Business Unit of Deallus, currently based in the City of London, but soon relocating to the USA. He has worked on many of
the key oncology indications, characterized by a high degree of innovation and complexity. Claudio possesses in-depth understanding of the clinical,
commercial and technological aspects associated with most of the developments in the oncology field. As well. at Deallus Claudio has been heavily involved
in crafting specific analytical and modelling tools to maximize the strategic value that CI can deliver to clients.
Prior to joining Deallus, Claudio worked as post-doctoral researcher and as a PhD student at the London Research Institute of Cancer Research UK, one of the
Top Ten cancer research institutes worldwide where he was described as "one face for the visionary outlook for cancer research". His PhD work was published
in two top ranking peer-reviewed scientific journals. Prior to that Claudio earned a degree in Biosciences and a Masters in Biotechnology.
_____________________________________________________________________________________________________________________________
|
| |
|
Deborah Dauber
Associate Director, Competitive Intelligence
Genentech USA, Inc.
Deborah has been with the Genentech Competitive Intelligence group for the past five years, supporting decision making for both R&D and Commercial teams.
As an individual contributor and later as the lead for the Immunology team, Deborah led competitive intelligence initiatives to investigate key competitors
(product and company-level), evaluate revenue impact of competition, and assess full market landscapes. Deborah has led Competitive Intelligence at
Genentech (as interim head and later as Associate Director) since 2007. Prior to joining Genentech, Deborah was a Consultant with WWMR, Inc., where she
worked with clients to design and execute market/opportunity assessments and managed the analyst team on custom projects. She has a B.S. in
Chemistry/Cellular and Molecular Biology from the University of Michigan, Ann Arbor, and a Ph.D. in Chemistry and Chemical Biology from the University of
California, San Francisco.
_____________________________________________________________________________________________________________________________
|
|
|
|
Brett J. Davis
Senior Director
Oracle Health Sciences
Brett Davis is a Senior Director in Oracle's Health Sciences Global Business Unit. In this role, Brett is responsible for shaping and driving Oracle's personalized
healthcare strategy and solutions. He works closely with leaders in healthcare and life sciences to help them leverage innovative information technologies
and applications to innovate and grow.
In addition to his role at Oracle, he is on the Board of Directors of the Personalized Medicine Coalition, is on HRSA’s Genetic Services Policy Project Advisory
Panel, is a Strategic Advisor for the Ben and Catherine Ivy Foundation for glioma research, and has been an invited speaker at industry meetings on
information technology’s transformative role in the health sciences.
Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences business. In this role, he was involved in helping shape IBM’
s strategy for health analytics, clinical genomics, high performance scientific computing, biobanking and translational medicine.
Prior to joining IBM, Brett led business development and marketing efforts at Genstruct, Inc., a Cambridge, MA based biotech. Previously he served as Senior
Product Manager and Director of Marketing for Viaken Systems, Inc., where he helped develop and market bioinformatics and knowledge management
solutions for pharmaceutical research.
Brett is a graduate of The Pennsylvania State University where he was enrolled in the accelerated Science BS/MBA Program, and graduated as the Eberly
College of Science Student Marshall.
Brett lives outside Philadelphia with his wife Virginia and two children, Owen and Emery.
_____________________________________________________________________________________________________________________________
|
| |
|
Jamie Denison-Pender
Managing Director
CIS Lifesciences
Jamie is the Managing Director of CIS Life Sciences, a global CI consultancy specializing in primary intelligence gathering, secondary due diligence,
analysis and consultancy within the pharma, biotech, generics and medical device markets. Jamie joined CIS back in 1997 and prior to that was an analyst
with a European strategic consultancy specializing in the energy and construction markets.
At CIS he’s been responsible for growing the business organically through a continuous enhancement of the offerings – focusing on marrying the skill sets of a
traditional CI agency with those of a strategic consultancy.
Jamie has a BSc in Mechanical Engineering and Business Studies from Oxford Brookes University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Richard DiCicco
Chairman
Harvest Moon Pharmaceuticals
Richard DiCicco co-founded Harvest Moon Pharmaceuticals by acquiring the pipeline of TCI Generics, a subsidiary of the renowned Technology Catalysts
founded by Mr. DiCicco in 1979. Harvest Moon Pharma develops high barrier to entry generic drugs and biosimilars. Currently there are 35 P-IV ANDA products
in the Harvest Moon Pharma pipeline. In biosimilars, Harvest Moon Pharma is commercializing EPO-alpha, beta-interferon 1a and 1b, peginterferon alfa-2b,
imiglucerase, filgrastim, pegfilgrastim, r-hu-insulin, glargine, lispro, etanercept, trastuzumab, rituxumab, bevacizumab, cetuximab and adalimumab). Mr.
DiCicco is a member of the Editorial Board of the Journal of Generic Medicines, a member of the Licensing Executives Society, and is widely published in
generics and biosimilars.
___________________________________________________________________________________
|
|
|
|
Sandipa Dublish
Director, Global Market Research
Eisai
Sandipa Dublish is Director, Global Market Research at Eisai Corp. In this role she manages all aspects of strategic business insights including Competitive
Intelligence. In her previous position as Director, Oncology Market Research with Bristol-Myers Squibb – Sandipa was an active user of Competitive
Intelligence. She therefore has a unique perspective on CI both as a provider and a user.
Sandipa holds a PhD. in Marketing from Florida International University and an MBA from Faculty of Management Studies, Delhi, India.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mark Edelstein
Senior Director, Market Research
Lundbeck
Mark Edelstein has been an active champion for the Marketing Research function for nearly 25 years, committed to, and passionate about raising the
standards, excellence and impact of this remarkable function. Currently, Mark is Senior Director of Marketing Research for Lundbeck Inc., in the Chicago
metro area, the U.S. affiliate of this Copenhagen-based pharmaceutical company. Prior to joining Lundbeck, Mark spent nearly 9 years as a global
pharmaceutical marketing research consultant. From 2008-2009, he was Vice President, Marketing Research for the new U.S. subsidiary of the Planning Shop
international – a UK based pharmaceutical marketing research consultancy. In 2001, Mark founded his own company, Mark Edelstein Consulting, Inc., where
he served as President and lead consultant to the global healthcare industry, focusing on cultivating Marketing Research and Business Intelligence. Prior to
starting up his own consulting firm, he spent 15 years on the healthcare manufacturer ("client") side, working for such Pharmaceutical leaders as Pharmacia,
Abbott Laboratories, Searle (Monsanto), and Merck & Co. Over that time, Mark was the lead market researcher driving the development and launches of some
of the industry’s most successful products, including Prilosec™, Biaxin™, Depakote™, and Celebrex™. Under his leadership, Marketing Research has brought
marketing insight and perspective to guide many other products in pre-clinical, launch and mature life-cycle stages.
Mr. Edelstein’s approach as a Research Consultant has always been to lead with vision, creativity, and a passion for excellence. Mark is a strong proponent of
“Knowledge Integration”: (1) probing to understand the full scope / constraints of the business issues and decisions to address; (2) “mining” the existing body of
data available from primary, secondary, syndicated research and “human capital” resources; (3) looking for synergies and gaps; (4) proposing customized
solutions.
Building on that foundation, one of Mark’s passions is to build a Competitive Intelligence function and expertise to complement Marketing Research for even
more comprehensive, proactive and strategic insights into our current and future markets and competitors.
Recently, Mr. Edelstein completed a 4 year term as a mentor-coach for students enrolled in an online certification program for marketing researchers
worldwide: Principles of Pharmaceutical Marketing Research – sponsored by the University of Georgia. He was very excited to be a part of this revolutionary
new course, and excited to work together with new colleagues from around the globe.
Among Mark’s professional affiliations, he is proud to be an active member of the American Marketing Association, the Pharmaceutical Market Research Group
(for which he has served as Vice President, Treasurer, Board Member, Program Chair, Facilitator, and Speaker over the past 20 years), the PharMarketing
Research Conference (serving as co-chair at the first annual meeting in 20`0), as well as being an active participant with the Pharmaceutical Business &
Intelligence Research Group, the Pharma CI Conference and the Society of Competitive Intelligence Professionals.
Mark began his professional career as a practicing Chemical Engineer for nearly 10 years, crediting his experiences at FMC and Procter & Gamble with
teaching him the art and skill of problem solving, project management, and the critical importance of collaborative work relationships. He holds a Bachelor’s
Degree in Chemical Engineering from Lehigh University in Bethlehem, Pennsylvania, and a Master’s Degree in Marketing from Drexel University, Philadelphia,
Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Beth Elliott
Vice President, Healthcare, Europe
Fuld & Co.
Beth Elliott is the Vice President of Fuld & Company’s European Healthcare Practice and has ten years experience in CI. She started her career as a Research
Analyst and has run over 200 projects within the Pharmaceuticals and Biotech sectors focusing across the value chain. Beth has also trained over 150 people
on how to illicit and protect information within congress settings.
_____________________________________________________________________________________________________________________________
|
|
|
|
Laura Farmer
Executive Vice President
The Larvol Group
Laura Farmer is the Executive Vice President for The Larvol Group. Over the past 17 years, she has led a wide range of strategy, marketing and
commercialization projects within the biopharmaceutical industry. Through her work, Ms. Farmer has developed expertise across numerous functional groups
and therapeutic areas including oncology, rheumatoid arthritis, and CNS.
Ms. Farmer was a contributing author of Forces Reshaping the Performance and Contribution of the U.S. Medical Products Industry, an in-depth industry
outlook, prepared for the Health Industry Manufacturers Association and presented to Congress, which helped precipitate regulatory reform for devices.
Before working with The Larvol Group, Ms. Farmer consulted and led projects with Straticore, Publicis Healthcare, Insight Strategy Advisors, True North
Partners, CSC Healthcare, and The Wilkerson Group for top pharmaceutical and biotech firms. She received a Bachelor of Arts cum laude in Political
Science with distinction and Pre-Medical studies from Yale University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Neelima Firth
Vice President, Healthcare Markets
Fletcher/CSI Healthcare Strategies
Neelima Firth is an experienced biopharmaceutical executive with extensive scientific, reimbursement, marketing and international experience in start up and
Fortune 500 biopharmaceutical companies including GSK, Bristol Myers Squibb, Sandoz and Amgen. As VP Healthcare Markets at Fletcher/CSI Healthcare
Strategies, Neelima influences strategic and tactical direction for Fletcher/CSI’s Managed Markets and General Healthcare practices. Working closely with
clients in the pharmaceutical and payer environments, Neelima is integral in designing and implementing effective competitive client market penetration
programs.
Previously, she was the Director of Strategic Planning and Operations at Amgen and led the strategic planning and operations group and worked closely with
the competitive intelligence group in gathering critical business information to aid informed decision making.
She worked at Amgen for 16 years in a series of increasingly senior roles in clinical, marketing and reimbursement in the UK and USA. Accomplishments
includes developing compendia strategy, managing Medicare and Medicaid marketing strategies, creating alliance management governance and
managing clear brand planning processes. She was instrumental in building the initial UK/European presence of Amgen to support the launch of new products.
In England, she was the President of AIOPI- Association of Information Officers in the Pharmaceutical Industry. She is a board member of the Association for
Strategic Planning in LA.
She has an Information Science degree from Leeds Metropolitan University in England, a Certificate in Legal Studies from Cambridge University in England
and an MBA from Pepperdine University in the US.
_____________________________________________________________________________________________________________________________
|
|
|
|
Carolyn J. Foster
Sr. Associate Director, Technology Assessment
Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Foster joined Boehringer Ingelheim Pharmaceuticals in 2001 and now heads the Competitive Technical Intelligence group for cardiovascular and
autoimmune diseases. In that capacity, she analyzes the external environment in the context of internal business issues, especially where technology is a
factor. Her internal clients include R&D, Marketing and Medical management and the analysts that support them.
Prior to her CTI career, Dr Foster spent 20 years as a biochemical pharmacologist in Cardiovascular Drug Discovery at Schering Plough working on drugs to
treat hypertension, atherosclerosis, thrombosis, and Parkinson’s Disease. Her published research focuses on G-protein coupled receptors and platelet function.
Dr. Foster studied chemistry at Swarthmore College, received an M.S. in biochemistry from Brown University and a Ph.D. in pharmacology from the University
of Medicine and Dentistry of New Jersey. She did post-doctoral research at the University of Pennsylvania in human genetics. She is a Fellow of the New York
Academy of Sciences where she has served as a member the conference planning committee, as Chair of the Biochemistry Section, and as head of the
Biochemical Pharmacology Discussion Group, an academia-industry consortium.
_____________________________________________________________________________________________________________________________
|
| |
|
Sean D. Freston
Managing Director, Asia Pacific
Proactive Worldwide
Sean Freston is the Managing Director, Asia-Pacific for Proactive Worldwide.
Sean has 15 years of experience living in and conducting business with China and the Asia-Pacific region. Over the past three years he has been based in
Shanghai tasked with business development in Asia for a global CRO. In his previous role with Proactive Worldwide, Sean led the pharmaceuticals practice in
conducting domestic and international competitive intelligence engagements. Over the course of five years, he was intimately involved with decision support
projects across multiple therapeutic areas from early discovery through marketing/lifecycle management initiatives.
He holds an MBA from Thunderbird School of Global Management, Arizona, and a BA from the University of Puget Sound, Washington.
_____________________________________________________________________________________________________________________________
|
|
|
|
FELIX W. FRUEH, Ph.D.
Vice President, Research and Development, Personalized Medicine
Medco Health Solutions, Inc.
Dr. Felix Frueh joined Medco in May 2008 to lead Medco’s personalized medicine research and development organization. In this function, Dr. Frueh
manages Medco’s expanding research efforts in personalized medicine, leveraging the newest developments in science to improve the safety and efficacy of
prescription drug care. He is also responsible for the development of Medco’s Personalized Medicine Research Center, which is under construction in
Whitestown, Indiana.
Prior to joining Medco, Dr. Frueh was Associate Director for Genomics at the U.S. Food and Drug Administration (FDA), where he built and led a core
genomics review team in the Center for Drug Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics review
group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and held senior positions at Transgenomic and Protogene
Laboratories.
Dr. Frueh’s academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC,
and postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.
_____________________________________________________________________________________________________________________________
|
| |
|
Kazumi Fujikawa
Director, Market Research
Pfizer, Japan
_____________________________________________________________________________________________________________________________
|
|
|
|
Tom Fussaro
Director, Government Relations and Public Policy
Millennium: The Takeda Oncology Company
Tom Fussaro acts as Director, Government Relations and Public Policy at Millennium: The Takeda Oncology Company. In his current role, Tom is responsible
for analyzing and responding to developments in federal and state government policy affecting Millennium and the biopharmaceutical industry – including
health care reform, comparative effectiveness research, PDUFA reauthorization and the creation of a regulatory pathway for the approval of biosimilars. Prior
to joining Millennium, Tom served as senior legislative assistant and health care policy advisor to Congressman Mike Ferguson (R-NJ, retired). While working
on Capitol Hill, Tom assisted Congressman Ferguson in his work on the House Energy & Commerce Committee during consideration of legislation such as the
Medicare Modernization Act, the Deficit Reduction Act of 2005 and PDUFA IV. Tom graduated from Wake Forest University with a Bachelor of Science in
Business and is currently pursuing a Master of Business Administration at the University of Chicago .
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Benjamin Gilad
Owner
Academy of Competitive Intelligence
Ben Gilad wrote the book on war games (literally, in 2009, Business War Games, Career Press). Since 1991, Ben has been running war games for the Fortunate
500, and training corporate managers in the art of predicting competitors’ moves. Most don’t listen to him, but they keep coming back calling his blunt style
refreshing. You can find more about him – but ask yourself why you want to know more first - at www.GiladWarGames.com and www.academyci.com. In his past
he was a good strategy professor (Rutgers U), a lousy junior police intelligence officer (Israel), and an old fashioned, free market economist (Ph.D 1981, NYU).
He still misses his undergrad classes at Rutgers who believed every word he said. He does not miss the MBA classes, though. He lives with his family in Boca
Raton, FL where he is the only one on his block who does not drive a Mercedes.
_____________________________________________________________________________________________________________________________
|
| |
|
Erik Glitman
Managing Director
Fletcher/CSI
Erik Glitman is a founder and Managing Director of Fletcher/CSI and serves as the Director of Global Operations, Research, and Strategy. As a founder of
Fletcher/CSI, he has been active in the Competitive Intelligence industry for over 15 years. He has worked with clients in areas such as automotive, electronics,
Healthcare, IT, kitchenware, machinery, pharmaceuticals, and Telco.
As an active part of the Fletcher/CSI consulting practice, Erik has extensive experience in working with clients to help them gain competitive advantage in the
marketplace through the integration of qualitative and quantitative CI collected from global sources. Fletcher/CSI, headquartered in Williston, VT, has been
active in the international CI marketplace since its inception and operates with 22 affiliate offices world-side. International clients use Fletcher/CSI consulting
services to understand competitor positions and develop strategies to increase profitability. A global leader in ethical CI, Fletcher/CSI has a history of
accurate and timely analysis on competitive situations while working with clients to develop effective strategies in rapidly changing markets.
Erik holds a B.S. degree in Economics from the University of Vermont, a B.S. in Environmental Studies from Johnson State College, and an M.S. in
International Affairs from American University. He is active with local charities and serves on the board of the Vermont Multiple Sclerosis Society Bike Tour, to
be held in August of each year.
_____________________________________________________________________________________________________________________________
|
| |
|
Thomas Han
Vice President US Marketing
Biovail
Mr. Han has over sixteen years of successful pharmaceutical industry experience including in-depth experience within strategic marketing, pre-launch
commercialization, product launches, brand marketing and field sales.
Mr. Han started his pharmaceutical career in field sales and was successfully promoted to positions within sales operations and marketing at Bristol-Myers
Squibb. He then moved into marketing roles at both Novartis and Schering-Plough. Mr. Han has had the opportunity to hold leadership roles on both small and
blockbuster brands.
In his current role, he is responsible for leading the product candidate identification and commercial assessment process for Biovail. This includes forecast
development and market research to validate and quantify the risks associated with each opportunity across multiple therapeutic areas.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Heerde
Director Strategy & BD
Bayer Schering Pharma
China
_____________________________________________________________________________________________________________________________
|
| |
|
Chris Hote
President
Digimind
Chris Hote is President of Digimind Inc. In his role, Hote works with organizations of all kinds to develop their intelligence framework to monitor, detect and
interpret change in their business environment. Hote also defines the strategy for easing adoption of competitive intelligence products throughout the CI
community.
Hote joined the Society of Competitive Intelligence Professionals in 2008 and participates in SCIP New England chapter. Previous to joining the Digimind
company Hote participated in multiple high-technology companies. Lastly, Hote co-founded the PolySpace start-up company focusing on the embedded
software market that got acquired by The MathWorks: a great experience to understand the role of competitive intelligence as an executive practitioner.
Hote has a PhD in physics, an MBA from Toulouse university and is a fellow student from MIT Sloan.
_____________________________________________________________________________________________________________________________
|
| |
|
Margaret Hsiao
CEO & Co-Founder
Harvest Moon Pharmaceuticals
Margaret Hsiao has over 20 years of technical and commercial experience in the Rx and OTC pharmaceutical industry for both the branded and generic drug
space. Harvest Moon Pharma product focus include biosimilars, high barrier to entry pharmaceuticals, and drug products for the emerging markets.
_____________________________________________________________________________________________________________________________
|
| |
|
Philip Lin Huang
Executive Director
Merck & Co Inc.
_____________________________________________________________________________________________________________________________
|
|
|
|
Colonel Ray S. Jeter
Chief, AFMS Innovations
Deputy Chief Medical Information Officer
Air Force Medical Systems
Colonel Jeter was born in Stuttgart, Germany. He received his Bachelor of Science in Biology from The Citadel in 1983 and his Doctorate of Medical
Dentistry from The Medical University of South Carolina in 1987.
As Chief of Innovations for the Air Force Medical Health System he interacts with DoD, government and academia identifying and exploring novel concepts,
new processes and disruptive technologies that have the potential to dramatically transform Air Force Medical Service capabilities. His office provides
strategic discovery and initial analysis of novel concepts. He tracks initiatives and translates them upon maturation to tactical AFMS requirements. Col Jeter,
as the senior dental subject matter expert at the Air Force Medical Support Agency provides functional expertise in the development of the MHS Electronic
Health Record Way Ahead and functions as the AFMS Deputy Chief Medical Information Officer.
He completed his Advanced Education in General Dentistry in 1996 and became a Diplomate of the Federal Services Board of General Dentistry in 1998. Col
Jeter is presently board certified by the American Board of General Dentistry. He practices comprehensive dentistry regularly at Bolling AFB and the Pentagon
Tri-Service Dental Clinic.
Col Jeter is married to Carol Joyce Fanning of Charleston, South Carolina. They have two children, Britton (18) and Claire (14).
_____________________________________________________________________________________________________________________________
|
|
|
|
Derek L. Johnson
CEO
Aurora WDC
Derek Johnson is Chief Executive Officer of Aurora WDC, a competitive and market intelligence firm founded in 1995 that works within all sectors including
CPG, Financial Services, Life Sciences, and Technology & Telecommunications. In addition to setting the strategy of the firm and being very involved in
client management and new business development, he is responsible for oversight of all client research and analysis engagements in terms of overall quality
control and calendar-based project management. Working with the firm’s senior research leaders, he carefully guides the process by which Aurora scopes all
research engagements in terms of project design and methodology, while also managing any conflict-of-interest issues and the client relationship overall.
Derek’s academic achievements include an MBA from the University of Wisconsin – Madison and a BBA in Finance and Economics from the University of
Wisconsin – Eau Claire. He was awarded SCIP’s Catalyst Award in 2010, served as Wisconsin’s SCIP chapter co-chair from 2007-2009, Program Chair of the
2009 SCIP International Conference, and is also a Chartered Financial Analyst (CFA).
_____________________________________________________________________________________________________________________________
|
|
|
|
Cliff Kalb
President
C. Kalb & Associates
Clifford Kalb currently serves as Vice President, Life Sciences at Wood Mackenzie, Inc.
In this capacity he provides thought leadership on industry issues and supports their knowledge based research and consulting practice.
Mr. Kalb has over thirty five years of experience in the pharmaceutical industry. Previously, he served as Senior Director, Strategic Business Analysis, in
Worldwide Human Health Marketing at Merck & Co., Inc. Prior to that, he held positions of increasing responsibility in sales, market research, health
economics, public policy management, marketing management, licensing, business intelligence and business development at Marion Labs, Pfizer and
Roche. He has also served as head of marketing and business development for a small biotechnology company.
Mr. Kalb has served as Chairman of the Conference Board Council on Competitive Analysis. He is also Past President of the board of directors of the Society of
Competitive Intelligence Professionals (SCIP), and Past President of the Pharmaceutical Business Intelligence and Research Group (PBIRG). Mr. Kalb is
widely published in the field of pharmaceutical industry intelligence and analysis.
In 2004, he was made a Fellow in SCIP, and received the Lifetime Achievement Award from PBIRG. In 2005, he was named one of top 100 most inspiring
people in the pharmaceutical industry by Pharmavoice magazine. Mr. Kalb holds a Bachelor’s degree in Biology and Psychology from Rutgers University, and
an MBA in Pharmaceutical Marketing and Economics from Fairleigh Dickinson University.
_____________________________________________________________________________________________________________________________
|
| |
|
Gerald Kunze
Associate Director, Market Research & Business Analytics
CSL Behring
Gerald Kunze is the Associate Director of Market Research & Business Analytics for CSL Behring, a $4 billion biopharmaceutical firm specializing in plasma
products and flu vaccines. His principle responsibilities include management of competitive intelligence, business analytics and market research for the
entire U.S. operation. Mr. Kunze’s group supports decision-making for the full range of businesses within CSL including immunology, bleeding disorders and
other rare diseases.
In addition to the functions he currently supports, Mr Kunze’s work experience spans a range of functional areas including marketing & sales, corporate
planning, finance, engineering and manufacturing.
Prior to his career in pharmaceuticals, he worked as a business consultant and corporate planner in the environmental and chemical industry.
Mr. Kunze formerly served as an adjunct professor of business in the Penn State system.
He earned his BSE in Chemical Engineering from Princeton University and a MBA from the University of Pittsburgh.
_____________________________________________________________________________________________________________________________
|
|
|
|
Susan Laufer
Director, Strategic Research
ImClone Systems Corp, a wholly-owned subsidiary of Eli Lilly & Co.
Susan Laufer, MS, is Director, Regulatory Strategic Research at ImClone Systems, a wholly owned subsidiary of Eli Lilly & Co., where she is in the process of
creating a new regulatory intelligence function. Prior to joining ImClone, Ms. Laufer was a member of sanofi-aventis’ Regulatory Intelligence team, where she
was responsible for covering oncology. Ms. Laufer began her career in Pharma 25+ years ago as an analytical R&D chemist with Teva Pharmaceuticals in
Israel, later moving to QA as a technical writer and then internal auditor, conducting internal GMP and ISO 9000 audits in four plants that manufacture and
package a variety of parenteral, liquid, and solid dosage products. Upon returning to the U.S. she established and implemented a GMP/CE quality system for
Light Age, Inc., a medical and scientific laser manufacturer, where as their first head of Regulatory Affairs she had full responsibility for regulatory compliance
and submissions, QA activities, SOP writing and training, and documentation control. Ms. Laufer holds a Masters degree in chemistry from Israel’s Weizmann
Institute of Science and a BA in both chemistry and biochemistry from Brandeis University, magna cum laude with honors in chemistry. She is also a proud
graduate of the Bronx High School of Science in New York.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mark Little
Vice President, Business Intelligence & Market Research
Covance, Inc.
Mark is currently Vice President, Business Intelligence at Covance Inc. in Princeton NJ. Mark joined Covance in 2002, and has since merged the intelligence
function with the market research function to form a more comprehensive, external-focusing unit at Covance. Before joining Covance, Mark worked in the
pharmaceutical industry with Glaxo, where he led a business-driven competitor intelligence operation that effected decisions related to both R&D and
commercial strategies.
Mark received a BS in chemistry from the University of North Carolina and a Ph.D. in biochemistry from The Ohio State University. Following his doctorate,
Mark received a National Science Foundation fellowship to conduct research at the University of Grenoble, in France.
Mark has been active with the Society of Competitive Intelligence (CI) Professionals, or SCIP, the 5000-membered organization for CI. Mark served as SCIP
President in 2001-2002, and as a Board member, 1998-2003, and is currently a member of the SCIP Education Committee. Mark is also a member of the
Intelligence Leadership Forum, a thought-leading intelligence organization established in 2003.
Mark has given frequent presentations on CI at conferences and business schools, and has authored several articles on the subject.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr Anna Mandinova
Professor
Harvard Medical School
Anna Mandinova is Professor at Harvard Medical School and Associate Member of the Broad institute of Harvard and MIT. Dr. Mandinova possesses
considerable experience in systematic small molecule technologies and their implication for cancer therapy. Her significant experience in this area has
played a major role in the development of a Chemical Genetics Core facility at the Massachusetts General Hospital, which she is currently directing.
Dr. Mandinova received her M.D. from the Medical University in Sofia, Bulgaria. She earned a Ph.D. in Cell Biology as part of the M.D./Ph.D. Program at the
University of Basel, Switzerland. Later, Anna Mandinova joined the laboratory of Dr. T. Maciag in the Center for Molecular Medicine at Maine Medical Center
Research Institute in Scarborough. As a research fellow in this lab, Dr. Mandinova was the first to demonstrate that IL-1a, similarly to FGF-1 is exported from
cells as a component of a multiprotein release complex in a stress-induced and copper-dependent manner. Her in vitro data served as a basis for clinical
studies pioneered by Dr. S. Marajver’s lab in which this approach was used to manage the progress of stage IV tumors in patients.
Anna Mandinova’s long-term goal as a physician scientist is to promote a translational research effort at Harvard medical School integrating the efforts of a
multidisciplinary team for drug development in the field of epithelial cancers.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Martinolich
Vice President and Senior Consultant
Fletcher/CSI Healthcare Strategies
Mr. Martinolich is the Vice President and Senior Consultant at Fletcher/CSI Healthcare Strategies. He is responsible for leading the company’s management
consulting services for their pharmaceutical and biotech clients. He is an accomplished veteran of the pharmaceutical industry with over 30 years of
experience in many functional areas within pharmaceutical companies.
His expertise includes all levels of sales, sales training, marketing management, business development, business operations, as well as strategic and
competitive insight. He has worked at the local, national and global levels and has been instrumental in pioneering many innovative programs, including
development of commercialization strategies, implementation and management that have been responsible for revenue growth globally.
___________________________________________________________________________________________________________
|
|
|
|
Liz Mathews
Principal
MedPredict
Liz has an extensive background in pharmaceutical marketing and competitive analysis. Prior to co-founding MedPredict, Liz worked as an independent
marketing consultant, completing numerous strategic marketing, business development, training and competitive intelligence projects for top tier
pharmaceutical clients, as well as clients outside the healthcare industry. Liz spent the first decade of her career in brand management with Procter &
Gamble, where she led strategic planning and marketing programs for pharmaceutical brands in all phases of their life cycles and in multiple therapeutic
areas.
Liz has an MBA from the University of Cincinnati College of Business and a BA from Siena College.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Martha Matteo
Corporate Advisory Board, BioXcel
Fellow (2010) and past President, SCIP
Former Director, Knowledge Management and R&D Planning, Boehringer Ingelheim
Dr. Matteo founded the Competitive Technical Intelligence (CTI) function at Boehringer Ingelheim Pharmaceuticals, Inc. in 1988 and responded to a board
request to help globalize it two years later. The function continues today, ever-adapting to the evolving needs of corporate decision-makers and those who
support them.
A biochemist by training and profession, Dr. Matteo developed the “CI perspective” through the Society of Competitive Intelligence Professionals (SCIP). An
active member since 1989, she served on the board of directors (2005-2008), as Vice President and President (2007). She has spoken at local and
international meetings, co-chaired two international CTI meetings and sponsored four academic interns from the University of Missouri at Kansas City, in
collaboration with Professor Patrick Bryant. Dr. Matteo has authored articles on CTI for Competitive Intelligence Review, Competitive Intelligence Magazine
(SCIP), Research and Technology Management (Industrial Research Institute) and two recent SCIP publications (Starting a CI Function and Competitive
Technical Intelligence). She was honored by SCIP (Catalyst Award, 2006; Fellow, 2010) and Frost & Sullivan (Lifetime Achievement in CI, 2007) for her
contributions to the field.
Dr. Matteo also remains active in the New York Academy of Sciences, where she meets regularly with pharma colleagues from industry and academia. At the
Academy, she chaired the Biochemistry Section and the Biochemical Pharmacology Discussion Group, served on the board of directors and was elected a
Fellow.
Dr. Matteo has a PhD in biochemistry from Brandeis University and was a founding faculty member of the University of Massachusetts/Boston. After an
academic career, she transitioned to applied research in industry, first at Union Carbide and then at Boehringer Ingelheim, where, after 8 years in the lab, she
moved into CTI. Dr. Matteo retired from Boehringer Ingelheim in 2006 as Director of Knowledge Management and R&D Planning. She remains active in
SCIP and the field of CTI, lecturing, writing and mentoring scientists and CI groups interested in CTI.
___________________________________________________________________________________________________________
|
|
|
|
Craig McHenry
Director, Competitive Intelligence, Market Analytics, Specialty Care Business Unit
Pfizer Inc.
_____________________________________________________________________________________________________________________________
|
| |
|
Gretchen Moss
Senior Manager, Business Services
Merial
Gretchen Moss is the Senior Manager, Strategy and Business Development at Merial. Over the past 15 years she has led competitive intelligence, business
development, and marketing projects across a range of industries and geographies. Gretchen entered the world of veterinary medicine in 2005 as the
Associate Product Manager for Frontline, one of the largest brands in the animal health care industry. After achieving record Frontline market share and
dispensing, she quickly rose to her current role at Merial. She has a BA in Economics from Mount Holyoke College in Massachusetts and a MBA in Marketing
and Operations Management from Carnegie Mellon University's Tepper School of Business.
_____________________________________________________________________________________________________________________________
|
|
|
|
Shacker Mourad, R.Ph, MBA
Founding President
NOAHSPHARM
Shacker is a consulting Health Care Professional and Practicing Pharmacist in a teaching hospital setting in the United States. He founded NOAHSPHARM
upon leaving AstraZeneca in 2008. Shacker’s 28-year pharmaceutical career spans the value chain in the US and abroad, where he worked for Eli Lilly,
Schering Plough, and AstraZeneca. He had held positions of increasing responsibilities in clinical development and sales and marketing, including the
Director of Competitive Intelligence.
Shacker holds an Executive MBA degree in Pharmaceutical Marketing from ST. Joseph’s University and Pharmacy Licenses in Pennsylvania and New York.
He is currently a graduate student of health policy at the Mayes College of Healthcare Business and Policy, at the University of the Sciences in Philadelphia.
_____________________________________________________________________________________________________________________________
|
|
|
|
Marjorie Norman
Director, Worldwide Competitive Intelligence
Pfizer
Marjorie G. Norman is Director, Worldwide Copetitive Intelligence for Pfizer, specializing in providing business and competitive intelligence to senior R&D
management. Prior to joining Pfizer in 2002, she was Director – Pharmaceutical Practice, at Fuld & Company, a competitive intelligence consulting firm and
a Senior Market Research Analyst at Johnson & Johnson Professional. Ms. Norman holds an MBA from the Graduate School of Management at Simmons
College and a BA in German and art history from Franklin & Marshall College. She recently returned from a six-month deployment at Population Services
International in Nairobi, Kenya, as part of the Pfizer Global Health Fellows program.
_____________________________________________________________________________________________________________________________
|
|
|
|
James (JJ) Owen, Ph.D.
Director, Scientific & Competitor Analysis
Millennium Pharmaceuticals
With over 6 years of experience in the competitive intelligence field, JJ is an Associate Director leading the Scientific & Competitive Analysis group at
Millennium Pharmaceuticals in Cambridge , MA . The group’s responsibilities include the monitoring of competition from R&D through Commercial and
working on cross-functional initiatives within the company.
Previously, JJ spent several years as an analyst within Business Development at AVEO Pharmaceuticals assisting with market research, public relations,
licensing partnerships and R&D collaborations. Other work experience include a stint with a Knowledge Management function at Millennium Pharmaceuticals
and managing teams of curators/editors while at Proteome/Incyte Genomics.
JJ holds a B.S in Microbiology from Mississippi State University and a Ph.D. in Cell Biology from Vanderbilt University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Valerie Pajak Glyptis
Senior Manager, Business Intelligence & Analytics
APP Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
|
|
|
Daniel Pascheles
Vice President, Head Global Competitive Intelligence
Merck & Co.
Dr. Daniel R. Pascheles is Vice President, Global Competitive Intelligence, and is based in Whitehouse Station NJ, at the Global HQ of Merck & Co., Inc.
His responsibilities include providing intelligence regarding business, research and development activities of competitors, as well as participating in, and
contribution to the strategy development process, the target identification for licensing and M&A activities.
Pascheles joined Merck & Co., Inc. early 2005 from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. He has worked
for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from
the same university. He has done additional study at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG). He is also member of the
Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES).
_____________________________________________________________________________________________________________________________
|
|
|
|
Christopher Perkins
Head of Global Competitive Intelligence
Roche Diagnostics - Diabetes Care
Christopher Perkins currently manages the Business Intelligence function for Roche Diabetes Care. Mr. Perkins has a BA (Hamilton College) and an MA (Penn.
State) in Mathematics.
Before coming to Roche, Mr. Perkins worked as a Market Research Manager in IBM’s PC Division. Prior to his current role at Roche, Mr. Perkins was Manager of
Market Research and also held an international assignment in Switzerland as Head of Market Insight and Analysis for Roche’s Insulin Pump business.
Mr. Perkins has had the opportunity to sit on the American Marketing Association’s Advanced Research Techniques program committee and has published in
the SIAM Journal of Numerical Analysis.
_____________________________________________________________________________________________________________________________
|
| |
|
Roslyn Potter
Research Fellow
Vertex Pharmaceuticals Inc
Twenty-nine years experience in pharmaceutical research, including nineteen years in scientific intelligence.
Vertex Pharmaceuticals, January 2009 to the present, providing scientific intelligence for preclinical and clinical teams. Also provides answers to scientific
questions in early research.
- Evaluation of the competitor landscape
- Target identification and target validity for early research
- Providing input to the research review committees
- Prediction of development risks of Vertex and competitor companies and suggestions for optimization for Vertex
DSM Pharmaceutical Products, 2004-2008: Scientific Intelligence used to identify top products for Sales Force
Consulting: Independent consulting to Pharma for preclinical projects. Also worked with consulting firms such as Fuld, and the Dunn Group
Hoffmann La Roche, 1981-1998: Started Scientific Intelligence in its current form in 1991
- Performed special projects for upper management
- Provided scientific intelligence to preclinical R&D
- Providing input into research review committees
- As part of preclinical R&D created Research Updates Online, an internal, interactive database containing hard and soft information derived from
external commercial databases, as well as from internal contributors
- Database was used by preclinical, clinical, patent law, M&A, and business development
_____________________________________________________________________________________________________________________________
|
| |
|
Pablo Prados
Senior Director Scientific Competitive Intelligence
Sanofi-Aventis
Pablo Prados is Head, Senior Director of Scientific Competitive Intelligence at sanofi-aventis. Pablo holds PhDs in Pharmaceutical Sciences from the
University Complutense of Madrid and the University of Tokyo, and received his MBA from Temple University. Pablo worked in Japan for 10 years in the
Pharma industry, holding positions in both R&D and Pharma Operations, such as Regulatory Affairs Manager with Nippon Schering, Strategic Planning
Director with Nippon Roche, New Products & Opportunities Head with Aventis Japan, and Business Analysis Head with sanofi-aventis Japan, before moving to
Paris in June 2007 to his current position.
_____________________________________________________________________________________________________________________________
|
|
|
|
John Rafa
Senior Manager, Business Intelligence
Covance
John Rafa currently holds the position of Senior Manager, Business Intelligence at Covance, a leading drug development services provider based in Princeton,
New Jersey . Mr. Rafa joined Covance in August 2006 and supports strategic planning, corporate development and marketing initiatives throughout the
organization. Mr. Rafa’s experience includes three years as an analyst for Strategic Business Research, providing consulting and market research services to
biopharmaceutical companies, and several years as a consultant for BearingPoint, where he delivered information systems solutions and management
consulting to Fortune 500 clients. His education includes a BS in Marketing from Villanova University and an MBA from Temple University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Chandra Ramanathan
Director, Commercial Development Oncology
Bayer HealthCare Pharmaceuticals
Dr. Chandra Ramanathan has been associated with pharmacy academia and pharmaceutical industry for more than 22 years. He has successfully applied
scientific insights to address business issues in oncology, immunology, Neuroscience and gastroenterology. He has extensive experience in Identifying new
licensing/business development opportunities and conducting scientific and commercial due diligence on both compounds and technology deals.
Dr. Ramanathan has contributed to the launch of Orencia (Biologic; Rheumatoid arthritis) and Sprycel (small molecule; Chronic Myelogenous Leukemia) by
incorporating competitive insights in marketing strategy development and execution. He has worked across the product development and commercialization
spectrum from discovery, clinical development to marketing. He has successfully worked in new product planning/product commercialization and has
contributed to the development of clinical and commercial strategy for early and late-stage compounds. He also played a key role in evaluating biosimilars
for potential opportunities and assessing risk for the commercial franchise.
_____________________________________________________________________________________________________________________________
|
|
|
|
Bobbi Sue Richardson
V.P. Institutional Sales
Sagient Research Systems
Bobbi Sue Richardson is Vice President of Institutional Sales at BioMedTracker. Bobbi Sue joined Sagient Research Systems over 13 years ago and was V.P.
of Institutional Sales for Sagient's product, PlacementTracker, and applied her sales experience into the healthcare industry. Bobbi Sue is responsible for the
growing BioMedTracker business in the pharmaceutical, biotech industry and financial industries, as well as managing client relationships.
BioMedTracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs
within a comprehensive and intuitive drug information database. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker
for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every
important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside subjective
clinical assessments on pipeline drugs worldwide.
Bobbi Sue has a Bachelor of Science – Finance from Northern Arizona University, College of Business Administration.
_____________________________________________________________________________________________________________________________
|
| |
|
Dr. Patrick Romano
Chief Operating Officer
Deallus Group
_____________________________________________________________________________________________________________________________
|
|
|
|
Shelby Rosen
Senior Strategic Planner
Draftfcb HealthCare
Since joining Draftfcb HealthCare in 2006, Ms. Rosen has executed promotional and advertising campaigns as well as supported new client acquisitions. As
Strategic Planner, monitoring competitive intelligence plays a critical role in ensuring strategic communications are differentiating.
Prior to joining Draftfcb, Ms. Rosen managed and executed custom-designed studies for healthcare clients at Hall and Partners Healthcare. Her therapeutic
areas of expertise include HIV, dyslipidemia, urinary incontinence, vaccination, auto-immune diseases, hormone therapy, and many others. Shelby received
her B.S.B.A, in Marketing and International Business from Washington University in St. Louis .
_____________________________________________________________________________________________________________________________
|
| |
|
Wayne Rosenkrans
Distinguished Fellow, MIT Center for Biomedical Innovation
VP Strategic Consulting, Fuld and Co.
Program in Ethics and Systems Medicine, Georgetown University
Chairman and President, Personalized Medicine Coalition
Chief Applications Officer, SciTech Strategies
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and
medicine.&n bsp; He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC based
organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare, and Chief Applications Officer for
SciTech Strategies focusing on scientific competency and capacity development for academia and industry. He is a former Director of External Relations for
the Personalized Healthcare Team and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he had responsibility for
long-range external relations strategy and policy development. He is active on several strategy and advisory boards at different organizations including the C-
Path Institute, Georgetown University, IBM, HP, and the Personalized Healthcare Initiative in the Secretary’s office at Health and Human Services. He has
presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development. He
holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston Univ., and received post-doctoral training in Cancer and Radiation
Biology at the Univ. of Rocheste r. Wayne lives in Malvern, PA, is married with two college-age children, and enjoys teaching martial arts (Tang Soo Do),
restoring antique/classic Fords, and aviation history.
_____________________________________________________________________________________________________________________________
|
|
|
|
Birgit Rubensdoerffer
Boehringer Ingelheim
Study of Chemistry / Master of Science of Chemistry (1989)
Senior Consultant at SVP Business Consultants Germany (till 1997)
Patent Analyst at Boehringer Ingelheim (till 2004)
CTI Manager at Boehringer Ingelheim (ongoing)
_____________________________________________________________________________________________________________________________
|
|
|
|
Laura Ruth, Ph.D.,
Director, Healthcare
Fuld & Company
Laura Ruth, Ph.D. is a Director with Fuld’s Pharmaceutical and Healthcare Practice. She received her Competitive Intelligence Professional (CIP™) Certificate
in December 2008 and published a Competitive Intelligence ‘How-To’ guide featuring Fuld expertise with Kalorama Information in November 2008. While at
Fuld she has investigated and evaluated a wide range of pharmaceutical, vaccine, managed care, and device competitive market issues, such as sales,
marketing, regulatory, pipeline products, and clinical trials.
Prior to joining Fuld, Ms. Ruth was an independent medical, science, and technology writer and consultant covering a wide range of science, technology,
business, policy, and regulatory topics. She provided a wide range of services to educational, biotechnology, journalism, and market research clients for six
years following a nine-year career as a biological chemistry laboratory scientist, which included work at Lawrence Berkeley Laboratories and Syntex.
The market research reports were written for Business Communications Company, Inc., Cambridge Healthtech Advisors, Drug & Market Development, and
Kalorama Information. Genetic & Engineering News reviewed two of the reports on DNA diagnostic technologies. In the fall of 2005, Ms. Ruth spoke as an
invited speaker at the European Nutrigenomics Organization (NuGO) meeting in Mallorca about the report: ‘Nutrigenomics: Impacts on Markets, Diets, and
Health.’ The National Academy of Sciences’ Nutrigenomics meeting in Washington, DC, in June 2006 featured the report as a current industry review.
As a scientific writer, Ms. Ruth created material for many academic and corporate organizations. Examples of the organizations include the National
Academy of Sciences, Analytical Chemistry, EMBO Reports, Oncology News International, and Catalyst Oncology. Most recently she published ‘Bio or Bust?’,
a review of biofuel environmental, economic, and policy issues for EMBO Reports.
Ms. Ruth holds a B.S. in chemistry from MIT and a Ph.D. in biological X-ray crystallography from the University of Pennsylvania. She set-up and executed an
NIH interdisciplinary post-doc in biological X-ray crystallography and molecular diagnostics at UCLA and Cedars-Sinai Medical Center, where she was a
member of three different labs. The projects included crystallization of alpha-L-iduronidase enzyme (Mucopolysaccharidosis I, Hurler Syndrome) and
development of a DNA diagnostic chip.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mary Ann Sarao
Sr. Director, Strategic Business Intelligence
DSM Pharmaceuticals
Mary Ann Sarao is currently the Sr. Director Strategic Business Intelligence at DSM Pharmaceutical Products, headquartered in Parsippany, NJ. In Mary
Ann's leadership position at DSM, she is building and executing Strategic Business Intelligence for three contract manufacturing business units: Biologics,
APIs and Secondary Manufacturing. She is responsible for a team in both the US and Vienna.
A native of New Jersey, Mary Ann brings 25 years of global pharmaceutical industry experience. Prior to DSM , Mary Ann held positions of increasing
responsibilities at Merck, Pfizer, J&J and Bristol-Myers Squibb in Strategic and Competitive Intelligence. Always interested in leveraging new technology, Mary
Ann designed multiple intelligence networks within the Pharma Industry. As a Director of Business Intelligence within Pfizer’s Corporate Legal Department,
Mary Ann had the unique opportunity to build an intelligence network to track counterfeit pharmaceutical products around the globe. During those four years
at Pfizer, consumer health and safety was Mary Ann’s primary concern. As a result, she received in 2006 an Award from Law Technology News for the Most
Innovative Use of Technology in a Legal Department.
Mary Ann is an innovative industry professionals who is dedicated to the creating a new paradigm shift in the Pharmaceutical Industry. A graduate of Seton
Hall University in Nursing, Mary Ann pursued a business career and attained her Masters degree from Rutgers University. Mary Ann’s understanding of the
complex healthcare environment, emerging markets, knowledge of biosimilars and intelligence gathering techniques significantly contributes to DSM's growth
in the Life Sciences.
_____________________________________________________________________________________________
|
|
|
|
Aaron Schacht
Executive Director/COO - Global External R&D
Eli Lilly
Aaron Schacht is Executive Director/COO for Global External R&D at Elil Lilly and Company. Aaron is an experienced and strategic executive leader and
entrepreneur in the Pharmaceutical/Life Science Industry; and has expansive experience in Drug Discovery, Drug Development and Life Science &
Information Technologies. Aaron brings a unique experience to new R&D models, having experienced both the large pharma and small, venture funded start-
up environment. Among Aaron’s accomplishments in this space are:
1) Devised/implemented novel VC vehicles to fund surplus early stage assets
2) Architect of Lilly’s R&D FIPNet Strategy and R&D Productivity Strategy
3) Leader of Lilly’s R&D Portfolio Management
4) Leader of mission critical and transformational R&D and Corp IT systems
5) Created 4 novel spinout R&D ventures
6) Founder of Venture Backed Biopharmaceutical Company
7) Co-Inventor of the Innocentive Concept
Aaron joined Lilly in 1990 as a medicinal chemist, holds a BS is Chemistry from the University of Illinois at Urbana-Champaign
___________________________________________________________________________________________________________
|
| |
|
Indra Sethy-Coraci
Principal Analyst
Boehringer Ingelheim
_____________________________________________________________________________________________________________________________
|
|
|
|
C. David Seuss
CEO
Northern Light
C. David Seuss is the CEO of Northern Light. Based in Cambridge, Massachusetts, Northern Light provides strategic research portals to the largest, most
research-driven, most innovative companies in the world. Clients include global organizations that are leaders in information technology, pharmaceuticals,
telecommunications, finance, and other industries. On behalf of its clients, Northern Light annually aggregates and indexes over 25 million research
documents from third-party research providers with a licensing value of over $2 billion. Northern Light’s own research focus is the automated analysis and
discovery of meaning from large repositories of market intelligence and technology research. Mr. Seuss has been the CEO of Northern Light since its
beginning in 1996. His prior experience includes founding Spinnaker Software, which he led from inception to publicly-traded company listed on NASDAQ.
Before Spinnaker, Mr. Seuss was a manager and consultant for the Boston Consulting Group. He holds an MBA from the Harvard Business School and a
bachelor of industrial engineering from Georgia Tech, and is a member of the board of advisors of the Tennenbaum Institute of Georgia Tech.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sanjiv Sharma
Vice President of Commercial Affairs
Nicox
Sanjiv Sharma has successful experience both at National and Global levels in Pharmaceutical Marketing, Sales Management, Strategic Planning, Market
Access, and Government Affairs. He has a sound knowledge of pharmaceutical markets and healthcare systems in both North American and Asia. Currently, as
a VP Commercial Affairs, He heads the commercial operations for NicOx SA and He is responsible for implementing a global commercial strategy for NicOx’
portfolio and defining and implementing the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first
compound in the CINOD class and the Company’s lead product for the treatment of the signs and symptoms of osteoarthritis. Sanjiv is also heads NicOx’s US
operations and is a member of the Company’s Executive Committee. Before joining NicOx, He was head of Strategic Marketing & Business Analysis (SMBA)
function for Biovail Pharmaceutical Inc, USA. In this role, he was responsible for new product commercialization and strategic life cycle management across
five therapeutic areas with a special focus on Wellbutrin XL and Ultram ER franchise: marketing of the current legacy product portfolio.
Before joining Biovail, he worked for Sanofi-Aventis and its predecessor companies for 15 years. During these 15 years, he experienced the success of several
companies’ key brands through various commercial roles, e.g. Cardizem, Lovenox, Altace, Texotare, Amaryl, Lantus and Exubera.
In the Global Marketing role in USA, He led several global cross-functional teams, in a matrix organization involving R&D, business development, brand teams
for USA, Japan and EU. Actively involved or led several strategic endeavors, e.g., Roadmap for Aventis Diabetes leadership; Non injectable insulins strategy:
North American Leadership Strategy; Aventis first Global Dynamic Diabetes Market Model for strategic planning and forecasting multiple opportunities, and
was also involved in several major Business Development deals and partnerships.
At Aventis Canada, He was a member of the Management Committee (PMC) .Led three functional departments within commercial affairs and led or involved
in five products launches.
For his contribution in building innovative healthcare solutions, he was awarded “ The Year 2000 Who’s Who in Healthcare” by Rogers Media, the largest
healthcare publishing group in Canada. He holds MBA with Distinction from Richard Ivey School of Business, University of Western Ontario, Canada, and was
designated as an Ivey Scholar for Scholastic Excellence.
_____________________________________________________________________________________________________________________________
|
|
|
|
Robert Siegmund
Director Global Commercial Analysis
Actelion
Dr. Robert Siegmund obtained a M. Sc. in Biochemistry from the University of Zurich, a Ph.D. in Genetics from the University of Vienna and a MBA from
London Business School.
He started his career in the pharmaceutical industry doing basic research in cancer biology at the Institute of Molecular Pathology in Vienna, which belongs
to the Boehringer Ingelheim Group. After MBA graduation Robert joined AMGEN where he worked in roles of increasing responsibility in the areas of market
research and strategic planning, first in the German affiliate and then in the International headquarters. In 2004 Robert moved to the global headquarters of
Roche to support the launch of a leading oncology product with market research, forecasting and competitive intelligence in his role as Business Analysis
Manager.
Since 2009 Robert is Director, Global Commercial Analytics at Actelion Headquarters in Switzerland. Robert is leading a team generating insights by market
research, competitive intelligence and business analytics. His team provides strategic advice and forward-looking decision intelligence to global strategic
marketing, business operations and global business development.
_____________________________________________________________________________________________________________________________
|
| |
|
Peter Simpson
Chairman
Biogenerics Australia
_____________________________________________________________________________________________________________________________
|
| |
|
Kim Slocum
Incoming President of HIMMS and former strategist at AstraZeneca
KS Consulting
Kim Slocum is President of KDS Consulting, LLC, an organization devoted to helping health care organizations understand the environment in which they
operate and assisting them in finding strategic, sustainable solutions to the business challenges they face. The company provides services to a growing list of
clients including payers, providers, life sciences firms, information technology firms, trade associations, and health care industry advisory organizations.
Before founding KDS Consulting in July 2006, Mr. Slocum worked for more than thirty-three years as an employee of a variety of pharmaceutical,
biotechnology and health care firms. Most recently he was Director of Strategic Planning and Business Development for AstraZeneca Pharmaceuticals where
helped to lead the company’s effort to develop innovative tools to better understand and shape its external environment. Over his corporate career Mr. Slocum
worked in a series of positions in sales, sales training, marketing, new product development, managed care marketing, disease management, health care
consulting, strategic planning and externalization efforts.
In recent years, Mr. Slocum has become deeply involved with health care information technology. He is a Fellow Member of the Healthcare Information and
Management Systems Society (HIMSS), a former member of the Society’s Board of Directors, a recipient of the Society’s 2005 Board Service Award, and a
recipient of the July 2005 “Spirit of HIMSS” award. He also continues to be active in health policy issues and among other activities he is the Chair Elect of
the Board of Trustees for the Texas Health Institute in Austin, Texas.
Mr. Slocum is a frequent speaker on issues related to the future of health care, the pharmaceutical industry, and the strategic importance of health care
information technology. He participated in the 2002 “Health Leaders” Roundtable on the pharmaceutical industry. He has also given over numerous
presentations to wide range of external audiences over the past several years, recently including, the Agency for Healthcare Research and Quality (AHRQ), the
Deputy Commissioners of the Food and Drug Administration, the University of Mississippi School of Pharmacy, the Harvard University School of Public Health
Policy, the European Pharmaceutical Marketing Research Association, the Pharmaceutical Marketing Research Group, the Society of Allied Chemical
Manufacturers Association, the National Managed Health Care Congress, the Healthcare Information and Management Systems Society, the World Healthcare
Congress, the Academy of Managed Care Pharmacy, the Western Medicaid Pharmacy Administrators’ Association, the National Lieutenant Governors’
Association, the National Governors’ Association, the Florida Association of Health Plans, US Senate staff, and members of various state legislatures.
In recent years, Mr. Slocum has also authored several pieces on health care. His first book, entitled “Consumer Directed Health Care, A 360 Degree View”
published in July 2008 by CRC Press describes the history of US health insurance, factors that contribute to its higher cost relative to other countries, and the
role consumers might be able to play in a transformed health care delivery system. His March 2007 article entitled “Trigger Points” was published in
Pharmaceutical Executive and described a vision for the future of pharmaceutical industry sales forces. His March 2009 article entitled “Health Care—
Rational or Rationed?” was published in Pharma Marketing News and described three alternate scenarios for the future of the biopharmaceutical industry.
Mr. Slocum earned his Bachelor’s Degree at the State University of New York at Geneseo and did his graduate studies in Business at Xavier University. He
resides in West Chester, Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kim Szymanowski
Competitive Intelligence Manager
Ethicon, a Johnson & Johnson Company
Kim Szymanowski has worked at Ethicon, a Johnson & Johnson medical device company for the past 24 years. She has worked in most functional areas
throughout the organization including:
12+ years in Suture, Needle, Packaging and Sterilization Manufacturing
5+ years in New Product Development
3+ years in Resource & Portfolio Management
1+ years in Strategic Planning
3 years in Competitive Intelligence (within Marketing)
Kim has helped build the Competitive Intelligence function and foundation over the past 3 years at Ethicon. This has included developing internal systems to
help improve access and disseminate intelligence to the organization. Several of these systems have been highlighted as a Best Practice within J&J and are
being leveraged across the sectors. With the medical device business being quite different from the pharmaceutical industry, data access and availability is
extremely difficult to obtain. This has resulted in creative approaches to build competitive pipelines using a number of different sources available from public
domains. The past three years have been an incredibly exciting time in the medical device Competitive Intelligence business - it’s been a tremendous
learning curve for Kim.
Kim has a Bachelor’s of Science degree in Industrial Engineering and has been a member of SCIP for the past 2 years.
_____________________________________________________________________________________________________________________________
|
|
|
|
Michael D. Taylor, Ph.D.
President & CEO
Ensemble Discovery Corp.
Michael D. Taylor, Ph.D. - Dr. Taylor is currently President and CEO of Ensemble Discovery Corp. in Cambridge, MA. He is also a member of the
Board of Directors of Cequent Pharmaceuticals. Dr. Taylor has been in the pharmaceutical industry for more than twenty years with extensive experience in
drug discovery and development, licensing and business development, and managing R&D alliances with pharmaceutical and biotech partners. Prior to
joining Ensemble Discovery in 2007, Dr. Taylor served as Senior Vice President for Pfizer¹s Global R&D division where he was responsible for global project
and portfolio management. In other positions with Pfizer (and previously Warner-Lambert/Parke-Davis), Dr. Taylor led discovery, and early- and late-stage
development projects across multiple therapeutic areas, including Lipitor® and Neurontin.® He has authored or coauthored 65 articles, reviews, and published
abstracts and holds 6 patents. Dr. Taylor earned a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and was awarded an NIH
postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Jack Tsai
Principal, Competitive and Technical Intelligence
Genzyme
Jack is a Principal Intelligence Analyst in the Genzyme Transplant business unit. Jack drives the use of market intelligence and analytics – including
epidemiology estimates, patient-based disease forecasts, product analogue models, and quantitative unmet need analysis – to facilitate better decisions
across business and science portfolio projects. Additionally, he provides ad hoc analysis of global industry and market trends in both Science portfolio projects
and business development initiatives.
_____________________________________________________________________________________________________________________________
|
|
|
|
Corina Turnes
Global Practice Leader Healthcare
Evalueserve
Corina Turnes is the Healthcare Practice Leader of Evalueserve. Evalueserve is a global knowledge solutions provider founded in the year 2000 offering
research and analytics solutions with an emphasis on higher complexity processes. Evalueserve has now grown to 2,300 people located in global delivery
centres in India, China, Chile and Romania.
Prior to joining Evalueserve Corina was a European Director with Pennside, a consulting business to the healthcare industry focusing on business intelligence
and competitive analysis. Prior to this she worked with a-connect, where she prepared the foundation for the global life sciences practice and supported the
building of a-connect’s presence in Asia out of the Hong Kong office. Corina also founded an independent consulting company focusing on the Healthcare
industry. Corina started off her career at McKinsey & Co. where she has been working on strategic and operational topics. Corina received a Masters in sports
science and physical education at the Swiss Federal Institute of Technology, Zurich.
Corina has worked on over a hundred projects within the Pharmaceuticals and Biotech sectors in many of the key therapeutic indications and has in-depth
understanding of the organizational, strategic and tactical aspects associated with drug development and commercialisation.
Since 2004 Corina is an Associate Faculty Member in the Department for Strategic Management of the zfu International Business School, Switzerland.
_____________________________________________________________________________________________________________________________
|
| |
|
Rakesh Verma
Director
CIS Lifesciences
Rakesh stated out is career as a vet in India. In order to further understand disease processes and immune responses he gained an MSc in Immunology with a
Distinction from the Royal Postgraduate Medical School, London and a Ph.D. in Immunology from Imperial College London in genetically engineering
recombinant therapeutic antibody fragments for clinical oncology applications.
At CIS Life Sciences Rakesh is a Director and responsible for maximizing the insight gleaned from pre-clinical and clinical programs with a particular focus on
Oncology, Immunology and biologics.
Prior to joining CIS Life Sciences, Rakesh had more than 12 years’ experience in the biopharmaceutical industry as a head of department at an oncology
focused company, Antisoma, where he initiated, developed and drove forward concepts and ideas to development stage projects. He is the inventor on
product-specific patent applications and has authored research articles, scientific reviews and book chapters. In addition, he has experience in writing
regulatory and CMC documentations, submitting patent applications, reviewing business development opportunities, due diligence and licensing. Rakesh has
made various presentations at international conferences, meetings and to collaborators and partners.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sheila Walcoff
Partner, McDermott Will & Emery LLP
former Chief Counsel to Secretary Leavitt, HHS
Sheila D. Walcoff is a partner in the Washington DC office of the law firm of McDermott Will & Emery LLP and a member of the Firm’s Health Industry Advisory
Group and co-leads the Life Sciences/Medical Products Government Strategies Team. Her clients include leading pharmaceutical and biotechnology
companies, innovative diagnostic companies, policy associations and coalitions.
A recognized health policy expert, Ms. Walcoff focuses her practice on personalized medicine and related science and health policy, FDA regulatory,
legislative and legal matters. Previously, Ms. Walcoff served as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS),
Associate Commissioner for External Affairs at the Food and Drug Administration (FDA) and the health policy team leader/senior health policy advisor to a
2008 presidential campaign. She also has significant legislative strategy and advocacy experience and served as the majority counsel to the U.S. House of
Representatives Armed Services Committee. Her ongoing pro bono work includes legislative and policy counsel to a national eating disorder association. Ms.
Walcoff serves on the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS), the Massachusetts Institute of Technology (MIT)
Center for Biomedical Innovation (CBI) Strategy and Policy Council, and the Board of the Friends of the National Zoo (FONZ).
Outside of her law firm practice Ms. Walcoff is an entrepreneur and co-owns several veterinary hospitals. She earned her J.D. from the Georgetown University
Law Center and resides in Maryland with her husband, Dr. Jeff Walcoff, their two young sons, and two Labradors.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sue Ward
Senior Director, Worldwide Competitive Intelligence
Pfizer
Sue Ward is currently Senior Director of Worldwide Competitive Intelligence within Pfizer’s Corporate Strategic Planning group. Previously within Pfizer, Sue
led the competitive intelligence team within Information & Knowledge Management. Prior to joining Pfizer, Sue worked in the UK as Associate Director of
Competitive Analysis for SmithKline Beecham (SB) (now GSK). Other positions held by Sue within SB included managing a Clinical Information group and
the Product Literature Information Service. Sue holds a BSc (Hons) in Biology from University College London and an MSc in Information Science from The
City University, London .
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Ben Weintraub
Director of Research
Wolters Kluwer Health
After completing his training in immunology and biochemistry, Dr. Weintraub began work as a financial analyst in 2000. Collaborating with Dr. Henderson, Dr.
Weintraub co-founded BiotechTracker, an online tool for investors. In 2004, he became a licensed security analyst with Hibernia Southcoast Capital covering
the biotechnology sector, and later performed the same role at Variant Research. In 2006, Dr. Weintraub joined Dr. Henderson and Dr. Zuckerman at Reuters
Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub’s team moved to Wolters Kluwer in January
2009.
Prior to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr. Weintraub performed biochemistry and
immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra , Australia . He earned his doctorate in Biology
from the University of California , San Diego , and a bachelor of science in Life Science from the Massachusetts Institute of Technology.
_____________________________________________________________________________________________________________________________
|
|
|
|
Thorsten Wichtendahl
Senior Manager, Strategic & Competitive Intelligence
Pfizer Australia
Thorsten has been working in the Competitive Intelligence space for over 10 years and currently leads the Strategic and Competitive Intelligence team at
Pfizer Australia. His expertise is in delivering strategic insights and advancing senior managements understanding of their industry’s competitive environment.
Besides Pharmaceuticals, he also has extensive experience in the Wealth Management, Financial Planning and Insurance sectors, focussing on strategic
planning, competitive intelligence, customer analytics and sales reporting.
He has a MBA in International Management and Finance, a Master in Accounting and a Bachelor of Business in European Business and Marketing. He is a
CPA and currently writes his PhD thesis in Strategic Management and Competitive Intelligence.
_____________________________________________________________________________________________________________________________
|
|
|
|
Friederike Wirtz-Brugger, Ph.D
Associate Director, Scientific Competitive Intelligence
Sanofi-Aventis
Twenty eight years experience in Pharmaceutical research both as a Research Scientist and Senior Manager of Scientific Competitive intelligence
Senior Manager, Scientific Competitive Intelligence (SCI) , Sanofi-Aventis, US and France (2003 - present)
- Providing and managing intelligence analyses of the competitive landscape for cardiovascular and
thrombosis indications as part of a global SCI group.
- Evaluation of competitor strategies, identification of trends and product licensing opportunities for
French managed company.
- Effective global communication of interpretation and recommendations based on competitive
analysis to the research community in US , France and Germany and global marketing and
development project teams.
Senior Research Scientist, Aventis Pharma, US and Germany (until 2003)
- Managing and leading several early drug discovery and research project teams in the area of multiples sclerosis and inflammatory neurological
disease processes.
- Extensive knowledge in disease areasof CV, Thrombosis and CNS.
- Played a leadership role in Aventis / Millennium Collaboration as a representative on both target
identification and validation teams.
Education:
Ph.D., Physiology and Neurobiology, UMDNJ (The University of Medicine and Dentistry of New Jersey) and Rutgers University, Graduate School, NJ, USA.
Diplom-Ingenieur, M.S. degree / Chemical and Biomedical Engineering, University Giessen, Germany.
____________________________________________________________________________________________________________________________
|
|
|
|
Richard Withers
CEO
Deallus
Richard is the CEO of the Dealllus Group. Following several years service as a military intelligence officer, Richard retired, went to Business School and
started consulting to the Pharmaceutical Industry on intelligence matters.
Over his career he has facilitated over 100 strategic workshops such as War Games and Scenario Analysis events and has advised CI Managers and their
Customers in R&D across to Marketing on what to expect from CI and how to derive maximum value from it.
_____________________________________________________________________________________________________________________________
|
|
|
|
Wendy Ye
Principal Competitive Intelligence Specialist
Medtronic Inc
Wendy Ye is a Principal Competitive Intelligence Specialist. She designed and implemented Competitive Intelligence program and process for Medtronic
Neuromodulation. She leads competitive analysis and created tools, web site to support strategic planning and business decision. Before joining Medtronic in
2004, Wendy worked for Lucent Technologies as Sr. CI specialist and project manager in telecommunication field.
Wendy also worked for GCC, a Boston based consulting firm on medical device and telecom related patent litigation support, where she provided Japanese
and US patent analysis and prior art search. Wendy started her career as a researcher and Biomedical Engineer at MIT, Division of Health Sciences and
Technology, and Harvard VA Medical Center.
Wendy received her BS from Zhejiang University, China and MS from Tokyo Institute of Technology, Japan.
_____________________________________________________________________________________________________________________________
|
| |
|
|
|
